MINUTES
INSTITUTIONAL BIOSAFETY COMMITTEE
DATE: August 14, 2026

Attendance: Total Attending: 9 **Voting Members Present**: 8

Called to Order: 10:04 a.m.

Name	Expertise	Present
Linda Cassidy, MS	Non-Voting Member	X
Sue Gotta, MS	rDNA; Select Agents	X
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	X
Botond Igyarto, PhD	Microbiology	
Loretta Kelly, Esq.	Non-Affiliated Community Member	
Kathleen "Kitty" Kono	Non-Affiliated Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	X
Sara Meyer, PhD	Cancer Biology	X
Suzann Ordile	Non-Affiliated Community Member	X
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	
Holly Ramage, PhD	Immunology & Microbiology	X
Michael Root, MD, PhD	Immunology & Microbiology	
Drake Stierman	Safety Officer	X
Megan Watson, MS	Lab Specialist	

MINUTES REVIEWED:
Minutes of the July 10, 2026 meeting were presented for review.

Motion to Approve: Kitty Kono
Seconded: Phil LaTourette
Total = 8; For- 6, Opposed- 0, Abstained- 2

NEW PROTOCOLS:

1. **Principal Investigator C.S.**
   IBC Control# 26-07-1037

Summary:
- This study involves G-protein receptors and associated signaling molecules that may be potential therapeutic targets for improvement of asthma treatment.
- This is an in vitro study.
- The principal risks identified were:
  - Human cell lines
  - DH5 alpha bacteria
  - XL-Gold bacteria
- Containment has been set to BSL-2.

Committee Review:
- This protocol was reviewed under NIH Category E.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol**.**
- Clarifications were requested.

- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

2. Principal Investigator C.S.
IBC Control# 26-07-1038

Summary:

- This protocol is testing molecular glue molecules for their ability to prevent loss of adrenaline receptor function in mammalian cells during heart failure.
- This is an in vitro study.
- The principal risks identified were:
  - Human cell lines
  - DH5 alpha bacteria
- Containment has been set to BSL-2.

Committee Review:

- This protocol was reviewed under NIH Category E.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol**.**
- Clarifications were requested.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

ADMINISTRATIVELY APPROVED ITEMS:
The KSI database indicates the following items have been given administrative approval since our last meeting:

August 14, 2026

Protocol #	PI - Initials	Form type	Comments
24-07-875	DT	Continuing Review	Active - questions related to database update answered
25-03-934	ZS	Amendment	Added virus, rDNA, and in vivo work
25-07-966	IM	Continuing Review	Active - attached updated clinical protocol
24-05-855	RS	Continuing Review	Active - open to enrollment, attached updated clinical protocol
25-07-966	IM	Amendment	Updated personnel & questions related to database update answered
21-07-412	LG	Continuing Review	Active - added virus, human cells, & rDNA
24-07-871	MD	Amendment	Updated IB
23-10-742	AMR	New	Work with virus, human materials, & rDNA
24-09-889	JC	New	Submittal of previously approved work
24-09-890	VA	New	Submittal of previously approved work
26-06-1035	LD	Amendment	Updated ABSL-1 to ABSL-2 for all bacteria in protocol
24-05-856	AN	Continuing Review	Active - questions related to database update answered
24-02-798	AS	New	Submittal of previously approved work
24-02-800	AS	New	Submittal of previously approved work
24-02-801	AS	New	Submittal of previously approved work
24-02-805	AS	New	Submittal of previously approved work
23-11-769	NH	New	Submittal of previously approved work

24-01-787	GC	New	Submittal of previously approved work
23-12-774	TM	New	Submittal of previously approved work
23-05-677-1	ZR	Continuing Review	Active - added rDNA & questions related to database update answered
23-10-741	AMR	New	Submittal of previously approved work
23-11-745	MC	New	Submittal of previously approved work
24-07-873	DM	Continuing Review	Active - questions related to database update answered
26-01-1006	RP	New	Submittal of previously approved work
23-10-740	UN	New	Submittal of previously approved work
21-08-419	CS	Amendment	Added hazardous chemical
22-12-614-1	MT	Amendment	Added retroviral vectors & human materials
24-10-893	MS	Amendment	Added updated IB and clinical protocol documents
23-08-714	TP	Continuing Review	Active - questions related to database update answered
24-01-781	AA	Amendment	Added hazardous chemical and recombinant DNA
22-09-560-1	MS	Continuing Review	Active - questions related to database update answered
23-03-667	CR	New	Submittal of previously approved work under MT
23-04-673	CG	New	Submittal of previously approved work
23-04-673	JB	New	Submittal of work with hazardous chemicals
21-07-402-1	AM	Continuing Review	Active - deleted use of hazardous chemical & updated personnel
21-07-402-1	AM	Amendment	Added hazardous chemical and recombinant DNA
22-09-563-1	DK	Amendment	Added storage of Hep C for new PI
21-08-423-1	YK	Continuing Review	Active - questions related to database update answered
23-11-750	AMR	Continuing Review	Active - questions related to database update answered

OTHER BUSINESS:
The committee chair welcomed three new IBC members, Suzann Ordile MS JD, Holly Ramage PhD, and Michael Root MD PhD.

-
- Commissioning of our 3rd floorABL3 and 5th floor BL3 labs hopes to be completed the last week of September.
- There are continuing issues with the new 5th floor fume hoods. Testing standards of the new hoods continues to be discussed.

Meeting Adjourned: 10:34 a.m.

Respectfully submitted for the IBC,

/s/Gerald Grunwald, PhD
Chair, Institutional Biosafety Committee

GG/lc